Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefixime transplacental transfer study in pregnant women for congenital syphilis prevention
ACTRN12625001176459Phase 3Not yet recruiting
- Sponsor
- World Health Organization
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cefixime in syphilis and congenital syphilis (CS), sponsored by World Health Organization. Primary endpoints: Maternal to cord blood cefixime concentration ratio, Maternal to neonatal cefixime concentration ratio and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
cefixime
03
Conditions
syphiliscongenital syphilis (CS)
Beyond the preview
Go deeper on ACTRN12625001176459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001176459.